Status:
RECRUITING
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
Lead Sponsor:
Zhejiang Cancer Hospital
Conditions:
Nasopharyngeal Carcinoma
Eligibility:
All Genders
65+ years
Phase:
PHASE2
Brief Summary
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
Eligibility Criteria
Inclusion
- Aged ≥65 years with newly pathologically confirmed NPC
- Karnofsky performance status ≥60
- Clinical stage III-IVA (Union for International Cancer Control and American Joint Committee on Cancer staging system for NPC, 8th edition)
- Adequate organ function
Exclusion
- Cancer history
- Prior radiotherapy, cytotoxic chemotherapy, immunotherapy or target therapy
- Life-expectance within 6 months
Key Trial Info
Start Date :
September 28 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2028
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06055816
Start Date
September 28 2023
End Date
June 30 2028
Last Update
September 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 325000